Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIEOP-BFM ALL 2017 phase 3 study in pediatric acute lymphoblastic leukemia
MOH_2019-05-05_006047Phase 3Not yet recruiting
- Sponsor
- דר' שרה אליצור
- Start
- Mar 2019
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of blinatumomab and bortezomib in acute lymphoblastic leukemia (ALL), mixed phenotype acute leukemia (MPAL) and acute undifferentiated leukemia (AUL) (8 arms), sponsored by דר' שרה אליצור. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
blinatumomabbortezomib
03
Conditions
acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)acute undifferentiated leukemia (AUL)
Beyond the preview
Go deeper on MOH_2019-05-05_006047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-05-05_006047.